Skip to main content

Table 1 The clinical trials of MSCs-EVs

From: Extracellular vesicles derived from different sources of mesenchymal stem cells: therapeutic effects and translational potential

Sources Diseases Intervention N. Pats Follow up State Location Number/Ref.
BM-MSCs Bronchopulmo-nary Dysplasia Bone marrow mesenchymal stem cell-derived extracellular vesicles 18 40 weeks Recruiting Boston Children’s Hospital Boston, Massachusetts, United States Brigham and Women’s Hospital Boston, Massachusetts, United States (and 3 more…) NCT03857841
BM-MSCs Coronavirus 5 times aerosol inhalation of MSCs-derived exosomes (2.0*10E8 nano vesicles/3 ml at Day 1, Day 2, Day 3, Day 4, Day 5) 30 3.5 months Not yet recruiting Ruijin Hospital, shanghai, China NCT04276987
UC-MSCs Chronic kidney disease Umbilical cord MSC-EVs (100 μg/kg/dose) 20 1 year Concluded Sahel Teaching Hospital Sahel, Cairo, Egypt [109]
UC-MSCs Macular degeneration Cord tissue MSC-EVs injected directly around macular hole 44 24 weeks Recruiting Tianjin Medical University Hospital Tianjin, China NCT03437759
UC-MSCs Dry Eye Umbilical mesenchymal stem cells derived Exosomes 27 12 weeks Recruiting Zhongshan Ophthalmic Center Guangzhou, Guangdong, China NCT04213248
UC-MSCs Diabetes mellitus Type 1 Two doses of MSC-EVs 20 3 months Unknown Sahel Teaching Hospital Sahel, Cairo, Egypt NCT02138331
AD-MSCs Osteoarthritis Secretome from adipose-derived mesenchymal stromal cells 24 3 years Not yet recruiting / NCT04223622